Cargando…
A framework for genomic biomarker actionability and its use in clinical decision making
The increasing scope and availability of genetic testing options for patients suffering from cancer has raised questions about how to use results of molecular diagnostics to inform patient care. For some biomarkers (e.g. BRAF mutations in melanoma), standards exist that outline treatments for indivi...
Autores principales: | Vidwans, Smruti J., Turski, Michelle L., Janku, Filip, Garrido-Laguna, Ignacio, Munoz, Javier, Schwab, Richard, Subbiah, Vivek, Rodon, Jordi, Kurzrock, Razelle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278279/ https://www.ncbi.nlm.nih.gov/pubmed/25593991 |
Ejemplares similares
-
Challenges and perspective of drug repurposing strategies in early phase clinical trials
por: Kato, Shumei, et al.
Publicado: (2015) -
Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms
por: Wheler, Jennifer J., et al.
Publicado: (2014) -
Circulating Tumor Cells: From the Laboratory to the Cancer Clinic
por: Agashe, Ruchi, et al.
Publicado: (2020) -
Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening
por: Adashek, Jacob J., et al.
Publicado: (2021) -
The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match
por: Subbiah, Vivek, et al.
Publicado: (2018)